Saphenous Vein Graft Intervention Complications: Difference between revisions
(New page: {{SI}} {{CMG}} {{EJ}} As with all medical procedures, complications for SVG intervention can occur. Risk factors for complications include: older graft age (>3-5 years), the pr...) |
No edit summary |
||
| Line 11: | Line 11: | ||
As mentioned above, prevention of [[no reflow]] should be attempted with [[embolic]] protection devices, pretreatment using [[nitroprusside]] and the avoidance of high-pressure inflations and unnecessary pre/post-dilation and oversizing. However, in the event that [[no reflow]] develops, it should be aggressively managed with intracoronary [[vasodilators]] (i.e. [[diltiazem]], [[nicardipine]], [[adenosine]], and [[nitroprusside]]). | As mentioned above, prevention of [[no reflow]] should be attempted with [[embolic]] protection devices, pretreatment using [[nitroprusside]] and the avoidance of high-pressure inflations and unnecessary pre/post-dilation and oversizing. However, in the event that [[no reflow]] develops, it should be aggressively managed with intracoronary [[vasodilators]] (i.e. [[diltiazem]], [[nicardipine]], [[adenosine]], and [[nitroprusside]]). | ||
{{ | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 16:12, 9 November 2010
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
As with all medical procedures, complications for SVG intervention can occur. Risk factors for complications include: older graft age (>3-5 years), the presence of thrombus, and diffuse disease.
Although PCI with stenting is effective for focal lesions, there is uncertainty regarding the best treatment for diffusely degenerated SVGs. In these cases, it is often a better choice to abandon the graft and intervene on the native vessel instead.
As mentioned above, prevention of no reflow should be attempted with embolic protection devices, pretreatment using nitroprusside and the avoidance of high-pressure inflations and unnecessary pre/post-dilation and oversizing. However, in the event that no reflow develops, it should be aggressively managed with intracoronary vasodilators (i.e. diltiazem, nicardipine, adenosine, and nitroprusside).